National PROspective Infrastructure for Renal Cell Carcinoma (PRO-RCC)
Launched by PROSPECTIVE RENAL CANCER COHORT FOUNDATION · Apr 6, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The PRO-RCC trial is a nationwide study focused on patients with renal cell carcinoma (RCC), which is a type of kidney cancer. The goal of this trial is to collect real-world information about patients' health and experiences to improve understanding and treatment of this disease. Researchers are looking for newly diagnosed patients or those who have metastatic RCC, which means the cancer has spread to other parts of the body. To join, participants need to be over 18 years old and speak Dutch.
If you or a loved one is eligible and chooses to participate, you will be part of a long-term study that gathers important health data and feedback about your experience with the disease and its treatment. This information will help shape future research and improve care for kidney cancer patients. The trial is currently recruiting participants, so if you're interested, it could be a great opportunity to contribute to advancements in kidney cancer treatment.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • newly diagnosed patients with RCC or synchronous metastatic RCC
- • metachronous metastasized RCC
- • age \>18 years
- • capable of understanding Dutch language
- Exclusion Criteria:
- • n/a
About Prospective Renal Cancer Cohort Foundation
The Prospective Renal Cancer Cohort Foundation is a dedicated clinical trial sponsor focused on advancing the understanding and treatment of renal cancer through innovative research and data collection. By establishing a comprehensive cohort of patients, the foundation aims to gather longitudinal clinical data that will inform the development of targeted therapies and improve patient outcomes. Committed to collaboration with leading academic institutions and healthcare professionals, the foundation seeks to enhance the scientific community's knowledge of renal cancer, ultimately facilitating breakthroughs in diagnosis, treatment, and management of this complex disease.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Deventer, , Netherlands
Eindhoven, , Netherlands
Groningen, , Netherlands
Den Bosch, , Netherlands
Nieuwegein, , Netherlands
Nijmegen, , Netherlands
Breda, , Netherlands
'S Hertogenbosch, , Netherlands
Amersfoort, , Netherlands
Utrecht, , Netherlands
Arnhem, , Netherlands
Rotterdam, , Netherlands
Apeldoorn, , Netherlands
Rotterdam, , Netherlands
Leeuwarden, , Netherlands
Roosendaal, , Netherlands
Zwolle, , Netherlands
Maastricht, , Netherlands
Haarlem, , Netherlands
Dordrecht, , Netherlands
Venray, , Netherlands
Den Haag, , Netherlands
Eindhoven, , Netherlands
Hilversum, , Netherlands
Amsterdam, Noord Holland, Netherlands
Emmen, , Netherlands
Rotterdam, , Netherlands
Patients applied
Trial Officials
Adriaan Bins, MD, PhD
Principal Investigator
Amsterdam UMC
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials